Skip to main content
NewslettersWatchlist

Cidara Thera(CDTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low11.57
Day High12.85
Open:12.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus
AllPennyStocks.com
Biotech Rallies Right Before Opening Bell
Business Wire
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
Business Wire
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Globe Newswire
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Globe Newswire
Cidara Therapeutics to Host Research and Development Day
Business Wire
Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory Teams
Globe Newswire
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Globe Newswire
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
Globe Newswire
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
Globe Newswire
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Globe Newswire
Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Globe NewsWire
Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress
Globe NewsWire
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021
Globe NewsWire
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Globe NewsWire
Cidara Therapeutics to Host Research and Development Day
Globe NewsWire
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary
Globe NewsWire
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Globe NewsWire
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Globe NewsWire
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Globe NewsWire
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
Globe NewsWire
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
Globe NewsWire
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe NewsWire
Cidara Therapeutics Provides Leadership Update
Globe NewsWire
Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Globe NewsWire
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference
Globe NewsWire
Cidara to Present at Mycology 2021 Conference
Globe NewsWire
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results
Globe NewsWire
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Globe NewsWire
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza

Profile

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.